Trabectedin
- Generic Name
- Trabectedin
- Brand Names
- Yondelis
- Drug Type
- Small Molecule
- Chemical Formula
- C39H43N3O11S
- CAS Number
- 114899-77-3
- Unique Ingredient Identifier
- ID0YZQ2TCP
- Background
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate Ecteinascidia turbinata and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
- Indication
用于治疗急性淋巴母细胞白血病、晚期软组织肉瘤及复发卵巢癌。
- Associated Conditions
- Metastatic Leiomyosarcoma, Metastatic Liposarcoma, Platinum Sensitive Relapsed Ovarian Cancer, Unresectable Leiomyosarcoma, Unresectable Liposarcoma
Sylentis Reports Positive Phase IIa Results for SYL1801 Eye Drops in Age-Related Macular Degeneration
• Sylentis announced that SYL1801, an investigational siRNA therapy administered as eye drops, met its primary endpoint in a Phase IIa study for neovascular age-related macular degeneration (nAMD).
• Over 71% of patients receiving the mid-dose level maintained visual acuity throughout the 6-week study period, with this dose achieving statistically significant improvement in visual acuity at day 42.
• SYL1801 represents a potential paradigm shift in AMD treatment, as it could replace uncomfortable intravitreal injections with a more patient-friendly eye drop formulation based on RNA interference technology.
Promising Pipeline for Soft Tissue Sarcoma Treatment Expands with 130+ Therapies in Development
• Global soft tissue sarcoma pipeline constitutes 125+ companies developing 130+ treatment therapies, with significant progress in clinical trials across various stages of development.
• FDA grants Orphan Drug Designation to Actuate Therapeutics' elraglusib for soft tissue sarcoma treatment, highlighting its potential to address unmet needs in this rare cancer.
• Novel approaches include tumor-targeting antibody-cytokine fusion proteins, intratumoral administration techniques, and GSK-3β inhibition, offering hope for improved outcomes in this challenging disease.
Boehringer's Ofev Nears EU Approval for Systemic Sclerosis-Related Lung Disease
• The EMA's CHMP has recommended approval of Ofev (nintedanib) as the first treatment for systemic sclerosis-related interstitial lung disease in the EU, marking a significant advancement for this rare condition.
• Ofev demonstrated strong market performance with sales reaching €677 million in H1 2019, representing a 22% growth primarily from its established use in idiopathic pulmonary fibrosis.
• With systemic sclerosis affecting approximately 2.5 million people worldwide and lung disease accounting for 35% of related deaths, this approval could significantly impact patient care.
Sonnet BioTherapeutics Advances SON-1010 Combination Trial for Sarcoma Treatment
• Sonnet BioTherapeutics expands Phase 1 SB101 trial to evaluate SON-1010 in combination with trabectedin for patients with unresectable, metastatic liposarcoma or leiomyosarcoma.
• The trial will enroll up to 18 patients, with a primary focus on safety, tolerability, and pharmacokinetics, utilizing the established maximum tolerated dose of 1200 ng/kg.
• SON-1010, a proprietary IL-12 formulation, aims to enhance immune response in the tumor microenvironment by converting 'cold' tumors to 'hot,' potentially improving treatment outcomes in earlier-stage patients.
Sonnet BioTherapeutics Advances Pipeline with Clinical Data and Strategic Partnerships
• Sonnet BioTherapeutics reported stable disease in 48% of evaluable monotherapy patients in the Phase 1 SB101 trial for SON-1010 (IL12-FHAB).
• Clinical trials evaluating SON-1010 in combination with Atezolizumab for Platinum-Resistant Ovarian Cancer (PROC) and trabectedin for advanced soft-tissue sarcomas (STS) are progressing.
• A licensing agreement was initiated in India for SON-080 in October 2024, focusing on Diabetic Peripheral Neuropathy (DPN) and reorganizing the leadership team.
• Sonnet anticipates initiating a clinical trial for SON-1210 with chemotherapy for advanced solid tumors and metastatic pancreatic cancer in H1 2025.
Global Biotechnology Market Projected to Reach USD 3.54 Trillion by 2033, Driven by Therapeutic Innovations
• The global biotechnology market is expected to grow from USD 1.68 trillion in 2024 to USD 3.54 trillion by 2033, representing a CAGR of 9.18%, according to Cervicorn Consulting.
• Red biotechnology, focused on medical applications, is projected to reach USD 649.31 billion by 2033, with monoclonal antibodies dominating the product segment.
• North America leads the global biotechnology market with the highest market share, while Asia Pacific is experiencing the fastest growth due to increasing investments and government support.
PharmaMar's Trabectedin Expands Development Portfolio with Multiple Cancer Indications
• Trabectedin (Yondelis), a marine-derived antitumor agent, is currently approved for advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer in combination therapy.
• The drug is undergoing development for multiple new indications including mesenchymal chondrosarcoma, recurrent meningioma, and various gynecological cancers, expanding its therapeutic potential.
• PharmaMar continues to investigate Trabectedin's applications, building on its success in treating liposarcoma and leiomyosarcoma patients who have received prior anthracycline-containing regimens.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath